Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

Graham Scotland; Charlotte Kennedy; Mari Imamura; David Cooper; Clare Robertson; Corinne Booth; Gordon Urquhart; Miriam Brazzelli

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

Graham Scotland, Charlotte Kennedy, Mari Imamura, David Cooper, Clare Robertson, Corinne Booth, Gordon Urquhart, Miriam Brazzelli

Research output: Book/Report › Commissioned Report

Abstract

Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

Original language	English
Publisher	National Institute for Health and Care Excellence (NICE)
Publication status	Published - 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@book{00fc8d69eb7c49f28963b8b9b8aaf49c,

title = "Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer",

abstract = "Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence",

author = "Graham Scotland and Charlotte Kennedy and Mari Imamura and David Cooper and Clare Robertson and Corinne Booth and Gordon Urquhart and Miriam Brazzelli",

year = "2020",

language = "English",

publisher = "National Institute for Health and Care Excellence (NICE)",

}

TY - BOOK

T1 - Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

AU - Scotland, Graham

AU - Kennedy, Charlotte

AU - Imamura, Mari

AU - Cooper, David

AU - Robertson, Clare

AU - Booth, Corinne

AU - Urquhart, Gordon

AU - Brazzelli, Miriam

PY - 2020

Y1 - 2020

N2 - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

AB - Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence

M3 - Commissioned Report

BT - Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

PB - National Institute for Health and Care Excellence (NICE)

ER -

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer

Abstract

UN SDGs

Fingerprint

Cite this